A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...

We recently published a list of Joe DiMenna’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular ...

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Natera (NASDAQ:NTRA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

Learn more about whether Alnylam Pharmaceuticals, Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor ...